Montreal Children's Hospital, McGill University, Montreal, QC, Canada; Department of Pediatrics, McGill University, Montreal, QC, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
Center for Adherence and Self-Management, Cincinnati Children's Hospital Medical Center; Department of Pediatrics, University of Cincinnati College of Medicine Cincinnati OH.
Am J Kidney Dis. 2018 Jul;72(1):30-41. doi: 10.1053/j.ajkd.2017.12.012. Epub 2018 Mar 27.
Poor adherence to immunosuppressive medications is a major cause of premature graft loss among children and young adults. Multicomponent interventions have shown promise but have not been fully evaluated.
Unblinded parallel-arm randomized trial to assess the efficacy of a clinic-based adherence-promoting intervention.
SETTING & PARTICIPANTS: Prevalent kidney transplant recipients 11 to 24 years of age and 3 or more months posttransplantation at 8 kidney transplantation centers in Canada and the United States (February 2012 to May 2016) were included.
Adherence was electronically monitored in all participants during a 3-month run-in, followed by a 12-month intervention. Participants assigned to the TAKE-IT intervention could choose to receive text message, e-mail, and/or visual cue dose reminders and met with a coach at 3-month intervals when adherence data from the prior 3 months were reviewed with the participant. "Action-Focused Problem Solving" was used to address adherence barriers selected as important by the participant. Participants assigned to the control group met with coaches at 3-month intervals but received no feedback about adherence data.
The primary outcomes were electronically measured "taking" adherence (the proportion of prescribed doses of immunosuppressive medications taken) and "timing" adherence (the proportion of doses of immunosuppressive medications taken between 1 hour before and 2 hours after the prescribed time of administration) on each day of observation. Secondary outcomes included the standard deviation of tacrolimus trough concentrations, self-reported adherence, acute rejection, and graft failure.
81 patients were assigned to intervention (median age, 15.5 years; 57% male) and 88 to the control group (median age, 15.8 years; 61% male). Electronic adherence data were available for 64 intervention and 74 control participants. Participants in the intervention group had significantly greater odds of taking prescribed medications (OR, 1.66; 95% CI, 1.15-2.39) and taking medications at or near the prescribed time (OR, 1.74; 95% CI, 1.21-2.50) than controls.
Lack of electronic adherence data for some participants may have introduced bias. There was low statistical power for clinical outcomes.
The multicomponent TAKE-IT intervention resulted in significantly better medication adherence than the control condition. Better medication adherence may result in improved graft outcomes, but this will need to be demonstrated in larger studies.
Registered at ClinicalTrials.gov with study number NCT01356277.
免疫抑制药物依从性差是儿童和青年人群中移植物早期丢失的主要原因。多组分干预措施显示出了一定的效果,但尚未得到充分评估。
本研究为一项评估基于诊所的依从性促进干预措施疗效的非盲平行臂随机试验。
2012 年 2 月至 2016 年 5 月,加拿大和美国的 8 个肾脏移植中心纳入了年龄在 11 至 24 岁、移植后 3 个月或以上的普遍肾脏移植受者。
所有参与者在为期 3 个月的入组期内接受电子监测,随后进行为期 12 个月的干预。被分配到 TAKE-IT 干预组的参与者可以选择接收短信、电子邮件和/或视觉提示剂量提醒,并在每 3 个月与教练会面,在此期间,根据前 3 个月的参与者依从性数据对参与者进行回顾。“以行动为导向的问题解决”用于解决参与者选择的重要的依从性障碍。被分配到对照组的参与者每 3 个月与教练会面,但不提供关于依从性数据的反馈。
81 名患者被分配到干预组(中位年龄 15.5 岁,57%为男性),88 名患者被分配到对照组(中位年龄 15.8 岁,61%为男性)。64 名干预组和 74 名对照组的参与者有电子依从性数据。干预组的参与者服用规定药物的几率显著更高(OR,1.66;95%CI,1.15-2.39),且接近规定时间服药的几率也显著更高(OR,1.74;95%CI,1.21-2.50)。
一些参与者缺乏电子依从性数据可能会引入偏倚。对于临床结局,统计学效力较低。
多组分的 TAKE-IT 干预措施显著提高了药物依从性,优于对照组。更好的药物依从性可能会带来更好的移植物结局,但这需要在更大规模的研究中得到证明。
ClinicalTrials.gov 注册,研究编号 NCT01356277。